ESTRELLA IMMUNOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $0.65 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2025-11-12
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.65.
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $0.46, a 0.00% change from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $0.46.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.65 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.65 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $0.65 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $0.65 10-Q · filed 2025-08-12 | $0.65 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.46 10-KT · filed 2025-03-25 | |||
| 2023-06-30 | $0.46 10-K · filed 2024-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |